FDA Drug Recalls

Recalls / Class II

Class IID-0634-2024

Product

Gabapentin Tablets, USP, 600 mg, 500-count bottles, Rx only, Manufactured by: Granules India Limited Hyderabad-500 081, India, Manufactured for: Granules Pharmaceuticals Inc., Chantilly, VA NDC 70010-227-05

Brand name
Gabapentin
Generic name
Gabapentin
Active ingredient
Gabapentin
Route
Oral
NDCs
70010-227, 70010-228
FDA application
ANDA217116
Affected lot / code info
Lot 1380040A, Exp. date July 31, 2025

Why it was recalled

Presence of Foreign Tablets; 3 fused tablets of Metformin ER 500 mg were found in bottle of Gabapentin Tablets

Recalling firm

Firm
Granules Pharmaceuticals Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
3701 Concorde Pkwy, Chantilly, Virginia 20151-1126

Distribution

Quantity
11,808 500-count Bottles
Distribution pattern
Nationwide in the USA

Timeline

Recall initiated
2024-07-31
FDA classified
2024-08-14
Posted by FDA
2024-08-14
Terminated
2025-06-12
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0634-2024. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Gabapentin · FDA Drug Recalls